Hepatitis C. Development of new drugs and clinical trials: Promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003
- 1 February 2004
- journal article
- review article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 39 (2) , 554-567
- https://doi.org/10.1002/hep.20065
Abstract
No abstract availableThis publication has 95 references indexed in Scilit:
- Structure–function analysis of the 3′ stem-loop of hepatitis C virus genomic RNA and its role in viral RNA replicationRNA, 2003
- Liver fibrosis – from bench to bedsideJournal of Hepatology, 2003
- Activation and Deactivation of a Broad-Spectrum Antiviral Drug by a Single Enzyme: Adenosine Deaminase Catalyzes Two Consecutive Deamination ReactionsAntimicrobial Agents and Chemotherapy, 2003
- Cell-Free Replication of the Hepatitis C Virus Subgenomic RepliconJournal of Virology, 2002
- Alpha Interferon Inhibits Hepatitis C Virus Replication in Primary Human Hepatocytes Infected In VitroJournal of Virology, 2002
- RNA interferenceNature, 2002
- Hepatitis C virus NS3 serine protease variability and evolution are strongly constrained by the need for structural and functional conservationJournal of Hepatology, 2002
- Persistence of YMDD variants after withdrawal of LamivudineJournal of Hepatology, 2002
- The Hepatitis C Virus (HCV)–Trimera Mouse: A Model for Evaluation of Agents against HCVThe Journal of Infectious Diseases, 2002
- THE IFNγ RECEPTOR:A Paradigm for Cytokine Receptor SignalingAnnual Review of Immunology, 1997